Rejuva NAD+ Pro 500mg is a sterile intravenous infusion of nicotinamide adenine dinucleotide (NAD+), manufactured by PENMIX Ltd. in South Korea as a 4th-generation NAD+ therapy. Each vial is formulated to support cellular energy pathways, DNA repair mechanisms, and professional IV therapy protocols, and it must be maintained under cold chain conditions between 2°C and 8°C from receipt through administration.
To learn more about Rejuva NAD+ Pro IV therapy, get in touch with the Medical Spa Rx support team.
Rejuva NAD+ Pro 500mg Vial: Product Specifications
- Active Compound: Nicotinamide Adenine Dinucleotide (NAD+)
- Regulatory Status: Professional-use IV therapy pharmaceutical
- Strength: 500 mg per vial
- Form: Sterile intravenous IV infusion solution
- Manufacturer: PENMIX Ltd.
- Country of Origin: South Korea
- Product Generation: 4th generation NAD+ therapy
- Storage: Temperature-controlled refrigeration (2°C to 8°C)
- Delivery: Cold chain required
- Package Content: 1 vial
What Is Rejuva NAD+ Pro 500mg?
Rejuva NAD+ Pro 500mg is a 4th-generation sterile intravenous IV infusion solution of nicotinamide adenine dinucleotide, produced by PENMIX Ltd. in South Korea. NAD+ is a coenzyme found in every living cell, where it supports energy metabolism and genomic stability pathways [2]. That central biological role is what has made it a focal point of professional IV therapy and injection therapy protocols over the past several years.
The RejuvaNAD+ Pro vial is supplied as a single unit, sometimes referenced by suppliers as the RejuvaNAD+ 1 vial format, and requires reconstitution before administration. Its 500mg strength represents the standard IV therapy dose per session, prepared according to manufacturer reconstitution guidelines, and the sterile intravenous IV infusion solution is intended strictly for administration by licensed healthcare professionals in a clinical setting.
The 4th generation designation reflects an advanced formulation approach within nicotinamide adenine dinucleotide (NAD) product development, and cold chain handling is non-negotiable: the product must remain at a temperature between 2°C and 8°C from storage through administration to preserve integrity [5].
Mechanism of Action and NAD+ Cellular Role
Understanding the role of NAD in cellular biology helps explain why this coenzyme has become a focus of professional wellness and recovery protocols.
Nicotinamide adenine dinucleotide (NAD+) is a central coenzyme in oxidation-reduction reactions, cycling between its oxidized (NAD+) and reduced (NADH) forms to shuttle electrons through mitochondrial respiration and drive ATP synthesis [2]. NAD+ also serves as a required substrate for poly(ADP-ribose) polymerases (PARPs), enzymes that detect and repair DNA strand breaks. Sustained PARP activity draws directly on cellular NAD+ reserves, which is part of why maintaining adequate NAD+ levels matters for genomic stability and the broader role in DNA repair [3].
Beyond energy and repair, NAD+ functions as a cosubstrate for sirtuins (SIRT1 through SIRT7), a family of deacetylase enzymes implicated in metabolic regulation, stress resistance, and cellular aging pathways [4]. Cellular NAD+ concentrations are known to decrease with age, which has driven interest in supplementation and IV repletion strategies aimed at supporting NAD levels for optimal cellular function [2][4]. Intravenous delivery bypasses first-pass gastrointestinal and hepatic metabolism, allowing direct systemic availability of the coenzyme compared to oral precursor forms.
Indications and Clinical Applications of Rejuva NAD+ Pro
Rejuva NAD+ Pro is intended for use by professionals across several NAD IV therapy and injection therapy applications.
Cellular energy support remains the most common clinical use: NAD IV therapy and injection protocols are used to support ATP production and address symptoms associated with low cellular energy output. Given its role in DNA repair enzyme function, NAD+ repletion is also positioned as a component of cellular preservation protocols focused on genomic stability [3].
Clinics use NAD+ infusion to support recovery, resilience, and general vitality programs for clients, and some practices have begun incorporating NAD+ formulations into broader aesthetic medicine offerings, including 4th gen NAD skin booster applications. Early research and clinical interest continue to explore NAD+ pathway involvement in cognitive function and athletic recovery [2], though the evidence base is still developing for several of these applications.
All indications above are intended for use by professionals only, within the scope of licensed clinical practice and applicable regional guidance.
Administration and IV Therapy Procedure
Rejuva NAD+ Pro must be reconstituted prior to use. Once reconstituted, the ingredient is added to an IV bag for infusion under professional supervision.
Administration is limited to sterile intravenous IV infusion solution delivery by a licensed healthcare provider in a clinical environment. Initial sessions are typically approached conservatively, with dose and infusion rate adjusted according to individual tolerability. The RejuvaNAD+ 500mg single box configuration allows a full 500mg dose to be prepared and administered in one session, or split according to the provider’s protocol.
Because body chemistry varies, effectiveness and reactions may also differ from patient to patient, and providers should monitor infusion rate and patient response throughout the session. In our experience, clinics that have integrated NAD+ infusion into established IV therapy menus tend to start with slower infusion rates across the board, since transient discomfort during administration is one of the more common reasons patients hesitate to return for follow-up sessions [1]. Adjusting the rate downward is a straightforward way to improve tolerability without changing the dose.
Storage and Cold Chain Requirements
Cold chain integrity is one of the most important operational considerations for any clinic handling Rejuva NAD+ Pro, and it is worth understanding early because it affects everything from how you source the product to how you schedule patient sessions.
Clinics must store Rejuva NAD+ Pro in the refrigerator at all times, maintaining a temperature between 2°C and 8°C [5]. Cold chain shipping must be continuous from the point of manufacture through delivery to the clinic, with no gaps in temperature control at any stage. Once reconstituted, the vial should be used promptly and kept refrigerated if it is not administered immediately.
Staff training matters here as much as equipment. Clinics should document temperature logs and verify that everyone handling the product understands proper cold chain procedures. When buying IV therapy products that require this level of temperature control, confirming that the supplier provides shipping documentation and temperature-monitoring guarantees is just as important as verifying the product itself. Any deviation from the required 2°C to 8°C range during storage or shipping should be treated as a potential compromise of product integrity, and the affected vial should not be administered until the deviation is evaluated.
Safety Profile and Considerations
As with any IV pharmaceutical, a full understanding of the risks and side effects associated with Rejuva NAD+ Pro is essential before administration.
The product is intended for use by professionals only, following a health history review and suitability assessment. Short-term tolerability data from clinical settings suggest that IV NAD+ is generally well tolerated when properly screened and administered, with negligible negative effects on organ function observed in monitored cohorts [1]. Because body chemistry varies, effectiveness and reactions may also differ between individuals, so monitoring during and after infusion is recommended.
Rejuva NAD+ Pro should not be used in pregnant or breastfeeding women, or in individuals with a known hypersensitivity to its active ingredient. Providers should screen for contraindications, document informed consent prior to administration, and have protocols in place for managing adverse events should they occur.
Legal Status and Regulatory Compliance
Rejuva NAD+ Pro is manufactured by PENMIX Ltd. in South Korea under Good Manufacturing Practice (GMP) standards [5]. As a sterile intravenous IV infusion solution, its regulatory classification and permitted uses vary by jurisdiction, and providers are responsible for confirming current local requirements before ordering or administering the product.
Supply is restricted to licensed healthcare settings and professionals. It is intended for use exclusively by professionals, not for direct consumer purchase or self-administration. Cold chain storage and transport are subject to pharmaceutical handling requirements in most regions, and shipping conditions should be verified with the distributor at the time of order.
Practitioners looking to buy Rejuva NAD+ Pro online should confirm that the supplier can provide lot documentation, certificates of analysis, and an unbroken cold chain record. Clinics that regularly buy NAD+ therapy wholesale tend to build a relationship with a single verified distributor rather than switching suppliers order to order, and it is worth taking the time to check for wholesale buying options that include standing accounts and recurring delivery schedules. The requirements to purchase Rejuva NAD+ Pro online differ by jurisdiction, so licensed professionals should verify what their regional regulations permit before placing an order.
Professionals who want to buy RejuvaNAD+ formulations beyond the Pro 500mg can review the full brand lineup for additional configuration and strength options. If you want Rejuva NAD+ Pro IV therapy for your practice, the Medical Spa Rx support team can help. Get in touch today for guidance on sourcing and cold chain logistics.
Regulatory information current as of August 2026. Healthcare providers should verify applicable local regulatory requirements.
Citations
[1] Reyna, Kirsten et al. “Intravenous infusion of nicotinamide adenine dinucleotide (NAD+) versus nicotinamide riboside (NR): a retrospective tolerability pilot study in a real-world setting.” Frontiers in aging vol. 7 1652582. 2 Feb. 2026, doi:10.3389/fragi.2026.1652582
[2] Covarrubias, Anthony J et al. “NAD+ metabolism and its roles in cellular processes during ageing.” Nature reviews. Molecular cell biology vol. 22,2 (2021): 119-141. doi:10.1038/s41580-020-00313-x
[3] Ruszkiewicz, Joanna A et al. “Fueling genome maintenance: On the versatile roles of NAD+ in preserving DNA integrity.” The Journal of biological chemistry vol. 298,6 (2022): 102037. doi:10.1016/j.jbc.2022.102037
[4] Navas, Lola E., and Amancio Carnero. “Nicotinamide Adenine Dinucleotide (NAD) Metabolism as a Relevant Target in Cancer.” Cells, vol. 11, no. 17, 24 Aug. 2022, article 2627, https://www.mdpi.com/2073-4409/11/17/2627. [5] Vita Medical. “RejuvaNAD+.” Vita Medical, 2026, www.vitamedical.com/rejuvanad.
Reviews
There are no reviews yet.